Compare CVS Health Corp (CVS) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs J M Smucker Co — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while J M Smucker Co trades at $117.46 (market cap $12.84B). The key difference: CVS Health Corp is far larger — about 9.5× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| CVS | SJM | |
|---|---|---|
Market Cap | $122.36B | $12.84B |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $126.35 |
52-Week Low | $65.51 | $89.53 |
Enterprise Value | $184.71B | $19.87B |
Dividend Yield | 2.78% | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
SJM trades at $120.16, up 1.14% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 results are pending. The company maintains a solid dividend track record, raising payouts for 25 consecutive years. Revenue growth is stable, but negative net income and ROE highlight profitability challenges amid high debt levels.
Outlook is cautiously optimistic with a consensus price target of $125.11 offering 4% upside. Key risks include persistent negative margins and elevated leverage, while opportunities lie in cost controls and brand strength. Investors should weigh dividend reliability against earnings volatility in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
